Immuneed recently completed a new share issue among existing shareholders
October 6, 2021
Immuneed is pleased to announce that the company has completed a new share issue among existing shareholders. The investment enables a continued extensive growth but also the important development and expansion of Immuneed’s service portfolio. It also allows successful recruitment and retaining of highly qualified personnel.
“This positive capital injection allows us to secure our strong business growth, meet the demand of new international customers and continue the exciting journey in strengthening Immuneed´s position as a specialized CRO-company within the important preclinical drug development. We are proud to be able to support and contribute to the vital development of safe and effective drugs” , Camilla Oldgren CEO of Immuneed.
Immuneed is a CRO enabling safe and effective drugs through tailored solutions in the early stages of development. Advanced therapies are increasingly being developed for patients in need, thereby putting pressure on the drug developers to produce qualified, effective, and safe matches. Immuneed combines our strong scientific knowledge with a versatile preclinical platform based on fresh, circulating human blood. Through our unique service, we cut our customer’s costs, and add value to drug development projects
Sofia is responsible for the commercial operations at Immuneed, with a strong focus on strategic marketing & customer excellence. Previously, she worked as Customer Success Manager for a technical software startup and brought her strong knowledge in customer relations management and digitalization with her to Immuneed. She graduated from the University of Gothenburg with a Master's degree in Business Creation and Entrepreneurship in Biomedicine.
2022 was a successful and eventful year for our team, and we are eager to continue building on that success in 2023.
Meet our QA Manager and learn more about how she ensures quality at Immuneed